At OncoSec, we are currently focused on two main disease areas - metastatic melanoma and triple negative breast cancer (TNBC). Metastatic melanoma is a form of skin cancer that has progressed to other parts of the body. There are different forms of skin cancer, but melanoma is the most serious. TNBC is an aggressive type of breast cancer that characteristically has a high recurrence rate within the first five years after diagnosis. While some breast cancers may test positive for estrogen receptor, progesterone receptor or human epidermal growth factor receptor 2 (HER2), TNBC tests negative for all three. As a result, TNBC does not respond to therapies targeting these markers, making it more difficult to treat. Both of these disease categories are very difficult to treat with the current standard of care. Through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients.
OncoSec encourages patients and care partners to research and explore educational resources.
Our core technology platform continues to advance through clinical trials for various cancers.
Our clinical trial findings on TAVO are significant but they are just the beginning!
We believe that knowledge holds the key to developing responsive treatments. OncoSec encourages patients and care partners to research and explore educational resources to better understand cancer and the organizations that are committed to offering treatment and support.